• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

EAI045

CAS No. 1942114-09-1

EAI045 ( EAI045 | EAI-045 | EAI 045 )

产品货号. M17407 CAS No. 1942114-09-1

EAI045 是一种变构抑制剂,针对耐药 EGFR 突变体,但避开野生型受体。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
10MG ¥466 有现货
50MG ¥1167 有现货
100MG ¥1797 有现货
500MG 获取报价 有现货
1G 获取报价 有现货
1 mL x 10 mM in DMSO ¥358 有现货

生物学信息

  • 产品名称
    EAI045
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    EAI045 是一种变构抑制剂,针对耐药 EGFR 突变体,但避开野生型受体。
  • 产品描述
    EAI045 ia a potent and selective EGFR inhbitor. EAI045 targets selected drug-resistant EGFR mutants but spares the wild-type receptor. EAI045 inhibits L858R/T790M-mutant EGFR with low-nanomolar potency in biochemical assays.
  • 体外实验
    EAI045 potently inhibits EGFR Y1173 phosphorylation in H1975 cells (EC50=2 nM), but not in HaCaT cells. EAI045 is an inhibitor of the L858R/T790M mutant with 1000-fold selectivity versus wild type EGFR at 1 mM ATP. Profiling of EAI045 against a panel of 250 protein kinases reveals exquisite selectivity; no other kinases are inhibited by more than 20% at 1 μM EAI045. EAI045 has high potency and selectivity for L858R/T790M mutation. In L858R/T790M-mutant NSCLC cell line H1975 cells, EAI045 decreases but does not completely abolish the EGFR autophosphorylation. In stably transfected NIH-3T3 cells harboring the L858R/T790M EGFR mutant, EAI045 shows the same activity. In L858R-mutant H3255 cells, EAI045 exhibits moderate activity. In the HaCaT cells, a keratinocyte cell line with wild-type EGFR, EAI045 does not show any activity of inhibiting EGFR phosphorylation. It confirms the selectivity of EAI045 for mutant EGFR.
  • 体内实验
    In a genetically engineered mouse model of L858R/T790Mmutant-driven lung cancer , remarkable tumor regression is observed in L858R/T790M-mutant mice treated with the combination of EAI045 and cetuximab. No response is seen in those mice treated with EAI045 alone. The same effect is seen in both L858R/T790M/C797S- engineered Ba/F3 cells and in mice carrying the L858R/T790M/C797S tumor xenografts. These assays clearly show that EAI045 can overcome resistance from acquired T790M and C797S mutations.
  • 同义词
    EAI045 | EAI-045 | EAI 045
  • 通路
    MAPK/ERK Signaling
  • 靶点
    p38 MAPK
  • 受体
    EGFR mutants
  • 研究领域
    Cancer
  • 适应症
    ——

化学信息

  • CAS Number
    1942114-09-1
  • 分子量
    383.4
  • 分子式
    C19H14FN3O3S
  • 纯度
    >98% (HPLC)
  • 溶解度
    DMSO : ≥ 28 mg/mL; 73.03 mM
  • SMILES
    c1ccc2c(c1)CN(C2=O)C(C(=O)Nc1sccn1)c1cc(ccc1O)F
  • 化学全称
    2-(5-fluoro-2-hydroxyphenyl)-2-(3-oxo-1H-isoindol-2-yl)-N-(1,3-thiazol-2-yl)acetamide

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1.Jia Y et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature. 2016 May 25;534(7605):129-32.
产品手册
关联产品
  • p38α inhibitor 4

    p38α inhibitor 4 (化合物10) 是一种选择性变构 p38α 抑制剂,IC50 值为 1.2 μM。p38α inhibitor 4 对 p38β、p38γ 和 p38δ 没有活性。

  • p38α inhibitor 1

    p38α 抑制剂 1 是 p38α 的抑制剂。

  • PAF (C16)

    C16-PAF (PAF (C16)) 是一种磷脂介质,是血小板活化因子,也是 PAF G 蛋白偶联受体 (PAFR) 的配体。C16-PAF 表现出抗凋亡作用,并通过激活 PAFR 来抑制 caspase 依赖性死亡。C16-PAF 是有效的 MAPK 和 MEK/ERK 激活剂。C16-PAF 诱导血管通透性增加。